Potentiation of a p53-SLP vaccine by cyclophosphamide in ovarian cancer: a single-arm phase II study (Q46920170)

26 December 2017

title

Potentiation of a p53-SLP vaccine by cyclophosphamide in ovarian cancer: a single-arm phase II study (English)

1 reference

26 December 2017

1 reference

9

1 reference

26 December 2017

Toos Daemen

15

object named as

Toos Daemen

1 reference

26 December 2017

Sjoerd H van der Burg

14

object named as

Sjoerd H van der Burg

1 reference

26 December 2017

Jan W Drijfhout

10

object named as

Jan W Drijfhout

1 reference

26 December 2017

author name string

Renee Vermeij

1

1 reference

26 December 2017

Ninke Leffers

2

1 reference

26 December 2017

Baukje-Nynke Hoogeboom

3

1 reference

26 December 2017

Ineke L E Hamming

4

1 reference

26 December 2017

Rinze Wolf

5

1 reference

26 December 2017

Anna K L Reyners

6

1 reference

26 December 2017

Barbara H W Molmans

7

1 reference

26 December 2017

Harry Hollema

8

1 reference

26 December 2017

Jaap Oostendorp

11

1 reference

26 December 2017

Ate G J van der Zee

12

1 reference

26 December 2017

Cornelis J Melief

13

1 reference

26 December 2017

Hans W Nijman

16

1 reference

26 December 2017

language of work or name

English

0 references

publication date

31 January 2012

1 reference

26 December 2017

International Journal of Cancer

published in

1 reference

26 December 2017

volume

131

1 reference

26 December 2017

page(s)

E670-80

1 reference

26 December 2017

issue

5

1 reference

26 December 2017

Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer

cites work

1 reference

Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer.

21 January 2018

1 reference

Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer

21 January 2018

1 reference

21 January 2018

Surfing the p53 network

1 reference

Live or let die: the cell's response to p53

21 January 2018

1 reference

Immunologic aspect of ovarian cancer and p53 as tumor antigen

21 January 2018

1 reference

Factors influencing p53 expression in ovarian cancer as a biomarker of clinical outcome in multicentre studies

21 January 2018

1 reference

Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes.

21 January 2018

1 reference

In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53.

21 January 2018

1 reference

Immunization with a P53 synthetic long peptide vaccine induces P53-specific immune responses in ovarian cancer patients, a phase II trial

21 January 2018

1 reference

Immunological and clinical effects of vaccines targeting p53-overexpressing malignancies

21 January 2018

1 reference

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

21 January 2018

1 reference

Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines

21 January 2018

1 reference

Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial

21 January 2018

1 reference

CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative

21 January 2018

1 reference

Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients

21 January 2018

1 reference

Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide

21 January 2018

1 reference

Cyclophosphamide enhances anti-tumor effect of wild-type p53-specific CTL.

21 January 2018

1 reference

P53-specific T cell responses in patients with malignant and benign ovarian tumors: implications for p53 based immunotherapy.

21 January 2018

1 reference

Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses

21 January 2018

1 reference

Clinical and immunologic effects of intranodal autologous tumor lysate-dendritic cell vaccine with Aldesleukin (Interleukin 2) and IFN-{alpha}2a therapy in metastatic renal cell carcinoma patients

21 January 2018

1 reference

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

Part II: chemotherapy for epithelial ovarian cancer-treatment of recurrent disease

21 January 2018

1 reference

Treatment of metastatic melanoma with an autologous tumor-cell vaccine: clinical and immunologic results in 64 patients.

21 January 2018

1 reference

Increase of CD4+ CD25+ regulatory T cells in the peripheral blood of patients with metastatic carcinoma: a Phase I clinical trial using cyclophosphamide and immunotherapy to eliminate CD4+ CD25+ T lymphocytes

21 January 2018

1 reference

Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation

21 January 2018

1 reference

Chemotherapy rescues tumor-driven aberrant CD4+ T-cell differentiation and restores an activated polyfunctional helper phenotype

21 January 2018

1 reference

Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1

21 January 2018

1 reference

WT1 peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and non-small cell lung cancer.

21 January 2018

1 reference

Tumor-infiltrating cytotoxic T lymphocytes as independent prognostic factor in epithelial ovarian cancer with wilms tumor protein 1 overexpression

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/IJC.27388

1 reference

26 December 2017

PubMed ID

22139992

1 reference

26 December 2017